Cagrilintide
Long-acting amylin analogue investigated alone and combined with semaglutide (CagriSema) for weight loss.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: AM833
Long-acting amylin analogue investigated alone and combined with semaglutide (CagriSema) for weight loss.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal7.3
- Mechanism confidencePathway specificity and clarity6.4
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.7
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Weight / fat reduction
2 studies- strongLau DCW, Erichsen L, Francisco AM, et al.
Cagrilintide 0.3-4.5 mg/wk monotherapy produced 6.0-10.8% weight loss vs 3.0% lira 3.0 mg and 3.0% placebo at 26 wk.
RCTn=7062021unreviewed - moderateEnebo LB, Berthelsen KK, Kankam M, et al.
Cagri 2.4 + sema 2.4 mg/wk produced 17.1% weight loss at 20 wk vs 9.8% sema alone.
RCTn=952021unreviewed
Appetite & food-noise suppression
1 study- weakHay DL, Chen S, Lutz TA, et al.
Reviews amylin/analog actions on satiety pathways (area postrema, NTS) - mechanistic basis for cagrilintide's appetite-suppressing effect; dedicated human appetite RCTs still pending.
Preclinical2015unreviewed
Cardiometabolic health
1 study- moderateFrias JP, Deenadayalan S, Erichsen L, et al.
CagriSema 2.4/2.4 mg/wk produced HbA1c -2.18% and weight -15.6% at 32 wk in T2D.
RCTn=922023unreviewed
Weight / fat reduction
1 regimenMild-moderate GI AEs; injection-site reactions.
26-wk investigational protocol; not regulator-approved as monotherapy.
Cardiometabolic health
1 regimenGI AEs predominant; pooled with sema profile.
32-wk investigational protocol; combination not separately marketed.
Appetite & food-noise suppression
1 regimenMild-moderate GI AEs.
Direct ad-libitum appetite endpoints absent; mechanism backed by Hay 2015 amylin review.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.